Portola Pharmaceuticals Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    What’s Portola’s Growth Strategy for Fiscal 2019?

    The company expects to benefit from the Andexxa opportunity in the US and Europe until fiscal 2025.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is Portola’s Andexxa Placed in the First Quarter?

    In its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a reorder rate of 55%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

    Analysts expect Amicus Therapeutics’ revenues to rise YoY by 89.66% to $173.05 million in fiscal 2019.

    By Margaret Patrick
  • uploads///pills _
    Company & Industry Overviews

    What Are Analysts Recommending for FOLD and PTLA in May?

    Amicus Therapeutics and Portola Pharmaceuticals both have a consensus “buy” rating in May.

    By Margaret Patrick
  • uploads///sw
    Company & Industry Overviews

    Why Portola Pharmaceuticals Rose 8.09% on January 4

    On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,

    By Daniel Collins
  • uploads///bacteria _
    Company & Industry Overviews

    Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today

    Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.

    By Daniel Collins
  • uploads///portola products
    Company & Industry Overviews

    Recent Developments for Portola Pharmaceuticals

    In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy.

    By Daniel Collins
  • uploads///Portola
    Company & Industry Overviews

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.

    By Daniel Collins
  • uploads///XARELTO
    Company & Industry Overviews

    Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto

    Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).

    By Sarah Collins
  • uploads///Xarelto
    Company & Industry Overviews

    How Is Johnson & Johnson’s Xarelto Positioned after 3Q17?

    In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    A Key Overview of Portola

    Portola Pharmaceuticals (PTLA) is a mid-cap stock with a market capitalization of ~$3 billion. It has a weight of 0.28% in the iShares Nasdaq Biotechnology ETF (IBB).

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    IBB Remained Flat Last Week

    The iShares Nasdaq Biotechnology ETF (IBB) gained marginally by 0.57% in the week ending September 18, 2015.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Biogen: An Investor’s Overview to a Leading Biotech Company

    One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.